Ptc Therapeutics Stock Price To Book

PTCT Stock

USD 45.25 1.41 3.22%

PTC Therapeutics fundamentals help investors to digest information that contributes to PTC Therapeutics' financial success or failures. It also enables traders to predict the movement of PTC Stock. The fundamental analysis module provides a way to measure PTC Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to PTC Therapeutics stock.

Other Current Liab Total Assets

Price To Book Ratio is likely to gain to -2.15 in 2025.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

PTC Therapeutics Company Price To Book Analysis

PTC Therapeutics' Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

P/B

MV Per Share

BV Per Share

More About Price To Book | All Equity Analysis

Current PTC Therapeutics Price To Book

1,743 X

Most of PTC Therapeutics' fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, PTC Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

PTC Price To Book Driver Correlations

Understanding the fundamental principles of building solid financial models for PTC Therapeutics is extremely important. It helps to project a fair market value of PTC Stock properly, considering its historical fundamentals such as Price To Book. Since PTC Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of PTC Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of PTC Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Accounts Payable	Long Term Debt	Short Term Investments	Total Liab	Property Plant Equipment	Current Deferred Revenue	Net Debt	Retained Earnings	Net Receivables	Total Current Assets	Short Term Debt	Common Stock	Net Tangible Assets	Capital Surpluse	Long Term Debt Total	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		-0.37	0.57	0.72	0.64	0.93	0.81	0.21	0.6	-0.9	0.89	0.95	0.62	0.88	-0.87	0.94	0.86	0.5	0.76	0.85	0.91
Total Stockholder Equity	-0.37		0.04	-0.82	0.18	-0.69	-0.6	0.03	-0.86	0.7	-0.71	-0.49	-0.71	-0.24	0.68	-0.38	-0.73	-0.72	-0.58	-0.23	-0.63
Accounts Payable	0.57	0.04		0.07	0.48	0.42	0.57	0.4	-0.06	-0.49	0.46	0.41	0.13	0.64	-0.5	0.63	0.39	0.11	-0.02	0.36	0.46
Long Term Debt	0.72	-0.82	0.07		0.16	0.9	0.66	-0.13	0.97	-0.86	0.88	0.85	0.88	0.57	-0.79	0.65	0.91	0.79	0.92	0.59	0.82
Short Term Investments	0.64	0.18	0.48	0.16		0.42	0.43	0.36	0.07	-0.36	0.27	0.62	0.24	0.55	-0.26	0.58	0.27	0.32	0.35	0.82	0.51
Total Liab	0.93	-0.69	0.42	0.9	0.42		0.86	0.14	0.82	-0.97	0.97	0.94	0.78	0.78	-0.94	0.87	0.96	0.69	0.84	0.75	0.96
Property Plant Equipment	0.81	-0.6	0.57	0.66	0.43	0.86		0.59	0.55	-0.86	0.85	0.74	0.74	0.7	-0.87	0.78	0.78	0.61	0.55	0.55	0.86
Current Deferred Revenue	0.21	0.03	0.4	-0.13	0.36	0.14	0.59		-0.24	-0.13	0.1	0.04	0.19	0.17	-0.2	0.21	-0.04	0.11	-0.14	0.07	0.18
Net Debt	0.6	-0.86	-0.06	0.97	0.07	0.82	0.55	-0.24		-0.78	0.81	0.76	0.79	0.43	-0.71	0.53	0.85	0.8	0.87	0.53	0.74
Retained Earnings	-0.9	0.7	-0.49	-0.86	-0.36	-0.97	-0.86	-0.13	-0.78		-0.98	-0.9	-0.76	-0.83	0.97	-0.9	-0.96	-0.65	-0.76	-0.69	-0.94
Net Receivables	0.89	-0.71	0.46	0.88	0.27	0.97	0.85	0.1	0.81	-0.98		0.88	0.77	0.79	-0.97	0.86	0.97	0.63	0.78	0.62	0.92
Total Current Assets	0.95	-0.49	0.41	0.85	0.62	0.94	0.74	0.04	0.76	-0.9	0.88		0.75	0.82	-0.8	0.87	0.89	0.69	0.88	0.88	0.92
Short Term Debt	0.62	-0.71	0.13	0.88	0.24	0.78	0.74	0.19	0.79	-0.76	0.77	0.75		0.54	-0.66	0.56	0.74	0.83	0.78	0.46	0.72
Common Stock	0.88	-0.24	0.64	0.57	0.55	0.78	0.7	0.17	0.43	-0.83	0.79	0.82	0.54		-0.79	0.95	0.73	0.37	0.58	0.72	0.82
Net Tangible Assets	-0.87	0.68	-0.5	-0.79	-0.26	-0.94	-0.87	-0.2	-0.71	0.97	-0.97	-0.8	-0.66	-0.79		-0.88	-0.92	-0.52	-0.67	-0.59	-0.9
Capital Surpluse	0.94	-0.38	0.63	0.65	0.58	0.87	0.78	0.21	0.53	-0.9	0.86	0.87	0.56	0.95	-0.88		0.83	0.44	0.64	0.81	0.92
Long Term Debt Total	0.86	-0.73	0.39	0.91	0.27	0.96	0.78	-0.04	0.85	-0.96	0.97	0.89	0.74	0.73	-0.92	0.83		0.65	0.81	0.67	0.93
Short Long Term Debt	0.5	-0.72	0.11	0.79	0.32	0.69	0.61	0.11	0.8	-0.65	0.63	0.69	0.83	0.37	-0.52	0.44	0.65		0.68	0.54	0.67
Net Invested Capital	0.76	-0.58	-0.02	0.92	0.35	0.84	0.55	-0.14	0.87	-0.76	0.78	0.88	0.78	0.58	-0.67	0.64	0.81	0.68		0.74	0.78
Net Working Capital	0.85	-0.23	0.36	0.59	0.82	0.75	0.55	0.07	0.53	-0.69	0.62	0.88	0.46	0.72	-0.59	0.81	0.67	0.54	0.74		0.82
Capital Stock	0.91	-0.63	0.46	0.82	0.51	0.96	0.86	0.18	0.74	-0.94	0.92	0.92	0.72	0.82	-0.9	0.92	0.93	0.67	0.78	0.82

Click cells to compare fundamentals

Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.

Competition

Predict PTC Therapeutics

Price Book Value Ratio Over Time

PTC Book Value Per Share

Book Value Per Share

(11.95)

At this time, PTC Therapeutics' Book Value Per Share is comparatively stable compared to the past year.

Based on the latest financial disclosure, PTC Therapeutics has a Price To Book of 1.74 K times. This is much higher than that of the Biotechnology sector and notably higher than that of the Health Care industry. The price to book for all United States stocks is notably lower than that of the firm.

PTC Price To Book Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses PTC Therapeutics' direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of PTC Therapeutics could also be used in its relative valuation, which is a method of valuing PTC Therapeutics by comparing valuation metrics of similar companies.

PTC Therapeutics is currently under evaluation in price to book category among its peers.

PTC Therapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of PTC Therapeutics from analyzing PTC Therapeutics' financial statements. These drivers represent accounts that assess PTC Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of PTC Therapeutics' important valuation drivers and their relationship over time.

	2020	2021	2022	2023	2024	2025 (projected)
Market Cap	4.0B	2.8B	2.7B	2.1B	1.9B	1.3B
Enterprise Value	4.2B	2.5B	3.0B	3.7B	3.3B	3.5B

PTC Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, PTC Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to PTC Therapeutics' managers, analysts, and investors.

Environmental

Governance

Social

PTC Fundamentals

	Return On Equity	-77.4
	Return On Asset	-0.0515
	Profit Margin	(0.50) %
	Operating Margin	(0.26) %
	Current Valuation	2.77 B
	Shares Outstanding	77.13 M
	Shares Owned By Insiders	2.51 %
	Shares Owned By Institutions	97.49 %
	Number Of Shares Shorted	4.2 M
	Price To Earning	(5.67) X
	Price To Book	1,743 X
	Price To Sales	3.87 X
	Revenue	937.82 M
	Gross Profit	299.37 M
	EBITDA	(330.34 M)
	Net Income	(626.6 M)
	Cash And Equivalents	288.43 M
	Cash Per Share	4.01 X
	Total Debt	2.23 B
	Current Ratio	1.23 X
	Book Value Per Share	(13.70) X
	Cash Flow From Operations	(158.42 M)
	Short Ratio	5.36 X
	Earnings Per Share	(5.94) X
	Price To Earnings To Growth	0.81 X
	Target Price	58.07
	Number Of Employees	988
	Beta	0.63
	Market Capitalization	3.49 B
	Total Asset	1.9 B
	Retained Earnings	(3.28 B)
	Working Capital	615.53 M
	Current Asset	355.95 M
	Current Liabilities	45.39 M
	Net Asset	1.9 B

About PTC Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze PTC Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PTC Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PTC Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for PTC Stock Analysis

When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC